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Abstract 
 
Between 2009 and 2012 there were 26 epilepsy-related deaths in the UK of women 
who were pregnant or in the first post-partum year. The number of pregnancy-related 
deaths in women with epilepsy (WWE) has been increasing. Expert assessment 
suggests that most epilepsy-related deaths in pregnancy were preventable and 
attributable to poor seizure control. While prevention of seizures during pregnancy is 
important, a balance must be struck between seizure control and the teratogenic 
potential of antiepileptic drugs (AEDs). A range of professional guidance on the 
management of epilepsy in pregnancy has previously been issued, but  little attention 
has been paid to how optimal care can be delivered to WWE by a range of healthcare 
professionals. We summarise the findings of a multidisciplinary meeting with 
representation from a wide group of professional bodies. This focussed on the 
implementation of optimal pregnancy epilepsy care aiming to reduce mortality of 
epilepsy in mothers and reduce morbidity in babies exposed to AEDs in utero.  
 
We identify in particular 
 
- What stage to intervene - Golden Moments of opportunities for improving 
outcomes 
- Which Key Groups have a role in making change 
- When - 2020 vision of what these improvements aim to achieve.  
- How to monitor the success in this field  
 
 We believe that the service improvement ideas developed for the UK may provide a 
template for similar initiatives in other countries. 
 
 
  
 Background 
 
Epilepsy is the most common life-threatening neurological disorder, affecting an 
estimated 50 million people around the world. About 30% of people with epilepsy 
will continue to experience seizures even with optimal medical management [1,2]. 
Uncontrolled convulsive seizures are a significant risk factor for epilepsy-related 
mortality, and, if occurring in pregnancy, pose a risk to the fetus. The risk of mortality 
due to epilepsy ranges from 0.1-1.0% per annum depending on a number of factors, 
most especially the frequency of generalised tonic clonic seizures [3]. Uncontrolled 
convulsive seizures not only are a significant risk factor for epilepsy-related mortality, 
but also pose a risk to the fetus if occurring in pregnancy. 
 
For women with epilepsy who are free of seizures, pregnancy is a time when full 
control of seizures should be maintained if at all possible while rationalising and 
minimising exposure to those antiepileptic drugs (AEDs). Where pregnant women 
continue to have seizures, the aim to minimise potentially harmful AED exposure 
[4,5] must be balanced with the need to minimise seizure frequency and severity. 
 
Maternal Mortality – Latest UK Findings  
In the United Kingdom (UK), maternal deaths have been regularly audited since the 
1950s, most recently under the auspices of MBRRACE-UK [6]. The latest iteration 
collected data on all maternal deaths in the UK from 2009-2012, demonstrating that 
neurological disorders comprise the second most frequent cause of maternal mortality 
during pregnancy. Epilepsy contributes to deaths in pregnancy and, uniquely among 
contributing neurological disorders, is associated with increased risk of maternal 
death both during and after pregnancy [7]. 
 
There are over 800,000 pregnancies per annum across the UK each year [8]. Over the 
latest 3-year audit period, there were 14 deaths during pregnancy in women with 
epilepsy. Closer analysis of these deaths [7] suggested that pre-partum deaths were 
preventable in 10/14 cases. It is thought that sleep deprivation, reduced medication 
adherence, high risk behaviours and suboptimal AED regimes may contribute to this 
increased mortality rate, all of which may be reduced with better care, in particular 
with shared decision making and patient education [7].  
 
There is evidence that the mortality rate during pregnancy and in the twelve months 
thereafter is higher than in women with epilepsy who do not get pregnant [9]. Action 
at this time is justified and appropriate [10] since pregnancy related deaths bring 
about an additional social cost, and there will be multiple contacts with health 
services presenting opportunities to pass on information and reinforce lifestyle 
changes that may reduce mortality and risk to both mother and child during and after 
pregnancy. What is more, poor quality healthcare provision offered to women with 
epilepsy (as measured by maternal deaths) is likely reflect poor quality of healthcare 
services in general, and epilepsy services in particular. 
 
Other reasons for improving maternal epilepsy care  
The potential for reducing maternal mortality is not the only reason to focus attention 
on the improvement of the pregnancy-related epilepsy care.  Pregnancy outcomes are 
worsened following AED exposure [11]. Additionally, some AEDs (particularly 
sodium valproate), whether used alone or in combination, carry an increased risk of 
major congenital malformations and neurocognitive difficulties following in utero 
exposure [4,5]. Such effects have been monitored in pregnancy registers such as the 
UK and Ireland Pregnancy Register for almost 20 years [12]. Registration is 
voluntary, and while the information is of enormous value, it only takes into account 
an estimated 25% of all UK and Ireland pregnancies in women with epilepsy. Higher 
registration rates would help support efforts to track the effects of all AEDs on major 
congenital malformations [12]. Further work with an enhanced registration rate could 
more effectively monitor and quantify AED-associated neurocognitive sequelae, 
marked by significant reductions in IQ and increased rate of autism with prenatal 
VPA use [13].  So while mortality data should be a call to action in improving 
epilepsy care, it is not the only one.  
 
Proposed way forward  
While guidelines are already in place promoting best practice in women of 
reproductive age, [14,15,16] there appears to be little coherence in efforts to embed 
identified ‘best practice’ into routine care, and so improve actual standards of care 
before and during pregnancy. Professional guidelines are well-meaning and evidence-
based, but tend to focus on single specialty groups, with little suggestion on how ‘best 
practice’ may be achieved across the range of different specialities and health 
professionals.  
 
In order to facilitate and effect change in UK practice, a meeting was called for 
17/12/2015 with representation  from a range of professional organisations (see 
appendix1) and in consultation with some voluntary sector organisations. Our aim 
was to review optimal ways of improving care and monitoring improvement. 
 
This document sets out the immediate and long-term aims of the group, with some 
practical suggestions on how these may be achieved. It will focus on three areas: 
 When to intervene - Golden Moments – Opportunities for Change 
 Whose Business is Improving Epilepsy Care? 
 2020 Vision – What we aim to achieve 
 
The approach described here and developed for the UK by healthcare professionals 
representing a range of different specialities may provide a template for similar 
initiatives in other countries.  
  
 
When to intervene - Golden Moments – Opportunities for Change 
 
Pregnancy-related healthcare encounters provide a series of opportunities for medical 
and nursing intervention. We recognise that prenatal advice should be prominent in 
epilepsy care from its earliest stages of diagnosis and treatment. Additionally, 
planning of pregnancy, diagnosis of pregnancy, antenatal care, delivery planning, and 
post-partum care all provie opportunities to consolidate this advice, to reinforce 
information provision, and empower patients to share in decision-making. We have 
named these the Golden Moments: 
 
Preconception 
All guidelines recognise the need for clear information on effects of epilepsy and 
AEDs on fetal and maternal health to be given at the time of diagnosis, since 
approximately half of pregnancies in women with epilepsy are unplanned [17,18] and 
patients with well controlled epilepsy (though still on medication) may lose touch 
with specialist services. Unfortunately, patients may see the provision of such 
information as irrelevant and it is therefore easily forgotten or unheeded in the lead up 
to pregnancies that may occur a decade or more later.  
While early (and repeated) iteration of up-to-date evidence is important in a clinical 
setting (Epilepsy Specialist Nurses are particularly adept at this) the group postulated 
that there may be other modes of communication (including upskilling of nurses in 
general practice and family planning clinics as well as pharmacists) that will reinforce 
the messages about the importance of avoiding severe or potentially harmful seizures 
and the more risk-inducing AEDs. This should build upon the toolkit recently 
produced in the UK by the Medicines and Healthcare products Regulatory Agency 
[19]. This specifically highlights the risks associated with taking AEDs including 
valproate (VPA) during pregnancy and encourages women of childbearing age and 
healthcare professionals to carefully consider alternative medications. 
In women on monotherapy with lamotrigine [20] or where AEDs have been titrated to 
minimum levels with retained control [21] there may be a case for measuring baseline 
serum AED levels, as this may help inform future dose increases during pregnancy 
[22]. Patients having previous AED related problems in offspring might benefit from 
review by a geneticist.  
 
Diagnosis of pregnancy 
The definitive diagnosis of pregnancy will usually lead to direct contact with general 
practice or obstetric services. Management of possible complications of early 
pregnancy such as vomiting (which may reduce AED blood levels) can be important 
in preventing exacerbation of epilepsy. In view of the recognised rate of self-initiated 
AED cessation when patients discover that they are pregnant, advice is needed not to 
stop AEDs precipitously or without prior expert advice. In any event, discovery of co-
existent epilepsy and pregnancy should prompt rapid specialist review to ensure 
optimisation of epilepsy control, protection from exacerbation of seizures, and 
appropriate dosing and utilisation of AEDs. Such specialist input at an early stage 
would help in enhancing adherence and empowering patients to take control of their 
own treatment and disease monitoring. The presence of any risk factors for seizure 
control worsening in pregnancy should be taken into account in planning any dosage 
changes [22]. 
That many patients will not book with a midwife before 12 weeks gestation is a 
separate but related issue outwith the remit of these guidance notes, but it reinforces 
the need for a robust pre-conception clinical relationship. Despite delayed diagnosis 
or registration of pregnancy, every effort must be made to expedite the neurological 
review once a patient has been referred, not least because  serum levels of some 
AEDs may fall early in pregnancy and reactive dosage adjustments may be 
appropriate (See table 1) [21]. 
 
 
Later in pregnancy 
Patients who are seizure free pre-pregnancy are likely to remain well controlled in 
pregnancy [22]. As pregnancy progresses, some argue that AED dosage adjustments 
(in particular in the case of lamotrigine) may be required to help clinicians 
compensate for falling AED serum levels [20] although the evidence for improvement 
in outcomes with therapeutic drug level monitoring is as yet lacking. Such AED 
levels are not always available, especially in a short enough time to justify frequent 
testing. AED dose adjustment may be indicated where there is a perceived high risk of 
deterioration in seizure control, or where seizure control worsens (Battino 2013).  
An agreed and comprehensive birth plan is essential, with input from both antenatal 
and epilepsy specialists. For patients whose AED doses were increased during 
pregnancy to maintain pre-pregnancy serum levels or in response to seizures, 
arrangements may need to be made to reinstate pre-pregnancy doses early in the post-
natal period. Breastfeeding should be specifically discussed. 
 
Post –partum 
Sleep deprivation and a change in lifestyle may combine to reduce adherence to 
medication and reduce seizure thresholds, with a subsequent risk of increasing seizure 
frequency and severity. Proper planning with specific individualised information 
should be given by heath providers to ensure optimal AED treatment and 
minimisation of seizure triggers. Putting safeguards in place before or very shortly 
after delivery would make most sense to prevent breakthrough seizures, and ensure 
that babies of mothers with epilepsy are not exposed to physical risks from seizures. 
At all stages, planning of breast feeding, opportunistic planning of future 
contraception and pregnancies will be important, but these are most relevant at this 
stage. Discussion about future parenting and the effect of epilepsy on safety in 
coming years could also take place around this time. 
 
 
  
Whose Business is Improving Epilepsy Care in pregnancy? 
 
Women with epilepsy and their children should be at the heart of all care and 
information provision for epilepsy in pregnancy. Professional input will be of little 
value if the patient and / or carers are not signed up to a process of enhancing quality 
and safety of epilepsy treatment. This ensures a major role for patient organisations 
and voluntary sector organisations in reinforcing key messages about optimal epilepsy 
management in and around pregnancy. Evidence-based information will come to 
naught if patients do not see the value for themselves. 
 
Joint effort by professionals and voluntary sector organisations 
Efforts to improve pregnancy outcomes in women with epilepsy are not only the 
responsibility of neurologists, health professionals involved in obstetric and 
emergency care or epilepsy organisations: it is important to recognise that women 
with mental illness, alcohol and substance misuse, learning difficulties, in social 
deprivation, or who are homeless may not engage effectively with traditional models 
of medical and social services. Those charged with providing support to these patients 
may have to help them engage with obstetric and neurological services or help 
mediate between patients and such services. Neurological and obstetric service 
providers on the other hand must make particular efforts to reach out to women with 
these additional problems as they are likely to be at particular risk of seizures and 
refractory epilepsy [23] which would suggest a higher risk of other pregnancy 
complications and SUDEP. 
 
As a minimum efforts to optimise pregnancy outcomes in women with epilepsy must 
involve Primary Care physicians and nurses, obstetricians / midwives, neurologists, 
epilepsy specialist nurses, pharmacists, health visitors, emergency department 
physicians, and psychiatrists. 
 
Roles of different contributors to healthcare for pregnant women with epilepsy 
These professionals need to collaborate to ensure coverage of the four ‘Golden 
Moments’. Each professional group may vary in the extent or focus of information 
provided, but we foresee a need for  
 
 Signposting and access to information about seizure control, safety and risk, 
and efficacy of AEDs 
 Signposting and access to information about the utility of vitamin supplements 
such as folate 
 Signposting specialist services needed at times of deterioration in seizure 
control 
 Signposting and access to information about particular obstetric needs in 
patients with epilepsy 
 
Health service commissioners should support the professionals delivering care and 
information by ensuring that responsive and joined up services are available for their 
patients. 
 
Table 2 provides more information about the responsibilities of the key professionals 
as well as patients themselves.   
 
Table 2: Responsibilities for each group 
 
i) What patients could do 
(When planning pregnancy, thinking they might be pregnant, becoming pregnant, 
booking into the obstetric services, planning delivery or preparing for the first year 
after delivery)  
 
 Be aware what effect their AEDs will have on contraception, fertility, and 
conception 
 Be aware what extra vitamins might help their baby to be fit and well 
 Plan for pregnancy (we realise this is not always possible) 
 Be active in ensuring availability of shared care pregnancy notes. 
 Request rapid access to specialist epilepsy services 
 Register online on the epilepsy in pregnancy register or ask their healthcare 
professional to register their pregnancy 
 
 
ii) What obstetricians and midwives should do 
 Ensure that all pregnant women with epilepsy are directed towards specialist 
epilepsy services at the first opportunity 
 Ensure that a plan is in place for action if seizures occur during delivery 
 Where patients are seizure free – epilepsy expert advice should be sought to 
establish which dosing regime is most appropriate 
 Where seizures continue – epilepsy expert advice should be sought to discuss 
treatment change and action should be considered to improve epilepsy control 
[24] 
 When discharge is planned after delivery, ensure that follow up is arranged in 
the next month with telephone or clinic contact. Discussion should include 
reinforcement of the benefits of breastfeeding. 
 
iii) What neurologists, epilepsy nurses, and epileptologists should do: 
 Ensure that all women are provided with information about epilepsy and 
reproduction from the earliest stages of their diagnosis 
 Ensure that rapid access is available for epilepsy review for anyone planning 
pregnancy, at any stage in pregnancy, and in the immediate post-partum 
period.  
 Provide individualised assessment of risk of drug continuation and drug 
withdrawal in pregnancy 
 Communicate using patient-held pregnancy notes 
 At each encounter with a woman of reproductive age taking AEDs, there are 
major questions to address 
1. Is the diagnosis of epilepsy secure? 
2. Is current treatment effective? 
3. Is it possible to reduce dose or number of AEDs? 
4. If VPA is being used, is it possible to withdraw VPA or reduce daily 
dose? 
 
iv) What pharmacists can do 
 Ensure that any woman of reproductive age prescribed VPA is counselled 
about the associated risks in pregnancy, and how to access advice regarding 
alternative treatments. The application of MHRA’s policy on VPA would be 
appropriate.  
 Advise adherence with current regime pending specialist review 
 
iv) What Emergency Physicians Should Do 
 Ensure that any woman of reproductive age receiving VPA is directed towards 
epilepsy specialist services to allow assessment of appropriateness of use +/or 
dose 
 Ensure WWE or first seizures are directed or referred to specialist services for 
urgent review if pregnant. 
 Communicate using patient-held pregnancy notes 
 
v) What Primary Care Physicians Should Do 
 Ensure that any woman of reproductive age receiving VPA is directed towards 
epilepsy specialist services to allow assessment of appropriateness of use +/or dose 
 Ensure WWE or first seizures are directed or referred to specialist services for 
urgent review if pregnant. 
 Ensure that rapid access is requested for epilepsy review for anyone planning 
pregnancy, at any stage in pregnancy, and in the immediate post-partum 
period.  
 
 
vi) What those Commissioning Services Should do 
 Ensure that epilepsy services are commissioned to include rapid access 
available (<2 weeks) for high risk groups 
 Ensure that Obstetric services are commissioned to deliver effective multi-
disciplinary epilepsy care for WWE 
 Ensure that robust and monitored referral pathways are in place facilitating 
timely access to specialist services for WWE 
 Ensure that the needs of WWE are met by collecting and monitoring patient 
engagement feedback 
 
 
 
 
 
  
 2020 Vision – What should we aim to achieve? 
 
At present there are a number of barriers to achieving optimal pregnancy outcomes 
for women with epilepsy in the UK: the rate of unplanned pregnancies means that it is 
difficult to carry out pre-pregnancy medication reviews and ensure folate 
supplementation. A lack of confidence in dealing with epilepsy in the obstetric 
community (including midwives) means that women with epilepsy (WWE) may not 
be referred to specialist epilepsy services. Limited access to neurology / epilepsy 
services may make it difficult for patients (and obstetric services) to obtain timely 
advice. There is currently no structured approach to information provision about 
epilepsy, AEDs and pregnancy by pharmacists. WWE may not be aware of pregnancy 
registers and health professionals may not prioritise patients’ registration sufficiently.  
 
While complete cessation of maternal epilepsy related deaths and fetal harm would be 
ideal, these challenges are clearly complex, and it is important to focus on achievable 
and measurable targets. The targets identified and the methods of measurement are 
summarised in Table 3. 
 
The authors realise that the key targets identified and the methods of measurement are 
specific to the United Kingdom. While the optimal management of epilepsy in 
pregnancy is a universal concern for those involved in care provision for patients with 
seizures, other health services will have slightly different problems and will need to 
identify different measures. However, we hope that our multidisciplinary approach 
and this summary of our discussion will inspire others to set similar targets for 
improvement in their countries. 
 
  
  
Table 3: 2020 targets and measures 
 
Target Measurement 
Reduce epilepsy-related maternal 
deaths by two thirds as measured by 
2020 
MBRRACE  
Increase registration rates with 
national registry to capture data on 
outcomes in 90% of pregnancies to 
WWE by 2020 (including 
miscarriages) 
UK and Ireland Pregnancy Register 
Ensure minimisation of unnecessary 
use of valproate in Pregnancy 
i) Monitor rates of VPA use in 
pregnancies registered with the UK 
and I pregnancy Register 
ii) Monitor Rate of provision of 
Epilepsy toolkit to women prior to 
booking with obstetric se 
rvices  
 
Ensure VPA doses are kept as low as 
possible  
Measured by analysis of UK and NI 
pregnancy data 
 
Quantify the numbers of pregnancies 
lost in WWE 
Measured by numbers of miscarriages 
in those registered with the UK and 
Ireland Pregnancy Register 
Increase the availability of resources   
 
  
  
List of Attendees 
 
 
ILAE UK Chapter - UK Chapter of the International League Against Epilepsy 
(ILAE UK) 
 
ABN - the Association of British Neurologists 
 
RCP - Royal College of Physicians (London) 
 
RCPSG - Royal College of Physicians and Surgeons of Glasgow, 
 
RCPE - Royal College of Physicians of Edinburgh 
 
RCOG - Royal College of Obstetricians and Gynaecologists 
 
ESNA - Epilepsy Nurse Association 
 
After the first draft, further input was sought from a range of voluntary sector 
organisations. Responses were received from Epilepsy Action 
 
 
  
Table 1 
Effect of pregnancy on serum levels and clinical effectiveness of AEDs 
 
Drug Pregnancy Effect 
on serum levels 
Timing  Clinically 
Significant? 
Carbamazepine Reduced levels Late pregnancy Variable - 
uncertain 
Gabapentin No change   
Lamotrigine Variably 
Reduced 
Progressive from 
1st trimester 
Potentially 
Levetiracetam Variably 
Reduced 
1st -3rd trimester Potentially 
Oxcarbazepine Reduced levels 1st-3rd Trimester  
Phenobarbital  Variably reduced  Unlikely 
Phenytoin Variably 
Reduced 
 Unlikely  
Topiramate Variably reduced 3rd Trimester Uncertain 
Valproate Variably reduced 3rd Trimester Unlikely 
Zonisamide  Uncertain    
Others: 
Felbamate, 
pregabalin, 
perampanel, 
retigabine, 
vigabatrin, 
lacosamide, 
eslicarbazepine 
Unknown   
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